Jubilant Radiopharma

What Jubilant Radiopharma does

Jubilant Radiopharma, the operating brand of Jubilant DraxImage Inc., is a Canada-incorporated (Kirkland, Québec) radiopharmaceutical business that develops, manufactures, and commercializes diagnostic and therapeutic nuclear medicine products for healthcare providers in the United States, Canada, and Colombia. It operates as a wholly-owned subsidiary of Jubilant Pharma, a diversified pharmaceutical conglomerate, and functions alongside a U.S. operating entity (Jubilant Pharma Holdings Inc., Yardley, PA) and a radiopharmacy services arm (Jubilant DraxImage Radiopharmacies, Inc.). The company's product portfolio centers on FDA- and Health Canada-approved radiopharmaceutical kits and generators—RUBY-FILL® (Rubidium Rb 82 Generator for cardiac PET), the DRAXIMAGE® line (DTPA, MAA, MDP-25, Sestamibi, MDP, Gluceptate, I-131 diagnostic and therapeutic capsules/solutions), HICON® Sodium Iodide I 131 Solution USP for thyroid disease, Drax Exametazime® for leukocyte imaging, Mertiatide and Sulfur Colloid—plus the SMART-FILL® automated radiopharmaceutical dispensing system as a hardware adjunct. Underlying technology is rooted in radiochemistry, lyophilized kit formulation, isotope generator engineering, and specialized manufacturing infrastructure required for handling radioactive materials.

The business model is B2B, selling radiopharmaceutical products and hardware directly to hospitals, imaging centers, and nuclear medicine departments via direct sales, an inside-sales account/RAM (Radiopharmaceutical Material) request system, and a network of radiopharmacy partners for localized preparation and last-mile delivery. Pricing is quote-based and not publicly disclosed, with multi-year contracts typical given the specialized nature, regulatory compliance burden, and radioactive material handling requirements. Customer segments are horizontal across nuclear medicine, cardiology, oncology, radiology, and endocrinology, with primary use cases in cardiac PET (RUBY-FILL), myocardial perfusion imaging (Sestamibi), pulmonary embolism V/Q scans (DTPA, MAA), bone scintigraphy (MDP-25), and thyroid disease diagnosis and therapy (HICON, I-131 capsules/solutions). The company also supports medical affairs activities including clinical trials (e.g., OPTIMUM), investigator-initiated research, continuing medical education grants, and patient/physician educational content.

Name

Jubilant Radiopharma

Legal name

Jubilant DraxImage Inc.

Website

https://draximage.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

101–250 employees

Short description

Jubilant Radiopharma (Jubilant DraxImage Inc.) develops, manufactures, and commercializes diagnostic and therapeutic radiopharmaceuticals and dispensing hardware for hospitals, imaging centers, and nuclear medicine departments across the USA, Canada, and Colombia.

Ownership category

akta.pro rank

Product category

Nuclear Medicine Pharmaceuticals

NAICS

Medical Equipment and Supplies Manufacturing (3391), In-Vitro Diagnostic Substance Manufacturing (325413), Surgical and Medical Instrument Manufacturing (339112), Irradiation Apparatus Manufacturing (334517)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Diagnostic Radiopharmaceuticals (SPECT/PET Tracers) (HLAIAGAA)

akta.pro secondary industries

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB), Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish) (HLAIAGAF), Radiopharmaceutical & Nuclear Medicine Distributors (HLAIAJAI), Nuclear Medicine Imaging Agents & Kits (Cold Kits/Precursors) (HLAIAGAG), Nuclear Medicine & Molecular Imaging (SPECT/PET) (HLAHABAE)

Keywords

• Diagnostic radiopharmaceuticals
• Nuclear medicine products
• Radiopharmaceutical manufacturing
• Therapeutic radiopharmaceuticals
• Cardiac PET imaging

Headquarters

HQ city

Kirkland

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Radiopharmaceutical Products: Sale of diagnostic and therapeutic radiopharmaceutical products for nuclear medicine imaging and treatment applications. Products include generators, isotopes, and radiopharmaceutical formulations sold to healthcare facilities.
2. Medical Device/Hardware Sales: Sale of specialized equipment including radiopharmaceutical generators and dispensing systems such as RUBY-FILL® and SMART-FILL® systems

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Jubilant Radiopharma develops, manufactures, and commercializes diagnostic and therapeutic radiopharmaceutical products for nuclear medicine applications. Its portfolio spans cardiac PET imaging (RUBY-FILL®), myocardial perfusion (DRAXIMAGE® Sestamibi), bone imaging (DRAXIMAGE® MDP/MDP-25), lung perfusion (DRAXIMAGE® MAA), renal and brain imaging (DRAXIMAGE® DTPA), thyroid imaging and therapy (HICON® I-131), and leukocyte labeling (Drax Exametazime®), alongside the SMART-FILL® dispensing system medical device. Products are sold directly to hospitals, imaging centers, and nuclear medicine departments across the USA, Canada, and Colombia.

Product overview

Jubilant Radiopharma (dba Jubilant DraxImage Inc.) is a radiopharmaceutical company that develops, manufactures, and commercializes diagnostic and therapeutic nuclear medicine products. The portfolio includes diagnostic imaging agents (RUBY-FILL® Rubidium Rb 82 Generator for cardiac PET, DRAXIMAGE® Sestamibi for myocardial perfusion, DRAXIMAGE® MDP-25 for bone imaging, DRAXIMAGE® MAA for lung perfusion, DRAXIMAGE® DTPA for renal/brain imaging), therapeutic products (HICON® Sodium Iodide I 131 Solution for thyroid treatment), medical devices (SMART-FILL® Dispensing System), and supporting products like Drax Exametazime® and Sulfur Colloid. The company operates in USA, Canada, and Colombia markets serving heart disease, thyroid disease, lung disease, and bone disease applications.

Differentiator

Problem solved

Functional benefit

Brands

• DRAXIMAGE: Radiopharmaceutical product brand including imaging agents and diagnostic products
• RUBY-FILL
• HICON
• SMART-FILL
• Drax Exametazime

Products and services

• RUBY-FILL® (Rubidium Rb 82 Generator) and Elution System A rubidium-82 generator and elution system used for PET myocardial perfusion imaging to assess heart disease and coronary artery conditions; sold to hospitals and imaging centers.
• DRAXIMAGE® DTPA A radiopharmaceutical chelate used for brain imaging, renal function assessment, and lung ventilation studies.
• DRAXIMAGE® MAA Macroaggregated albumin used for pulmonary perfusion imaging to detect pulmonary embolism and assess lung function.
• DRAXIMAGE® MDP-25 A bone imaging agent used for skeletal scintigraphy to detect bone metastases, fractures, and bone disease.
• DRAXIMAGE® Sestamibi A myocardial perfusion imaging agent used for detecting coronary artery disease and evaluating heart function.
• Drax Exametazime® A radiopharmaceutical used for labeling leukocytes in white blood cell imaging to detect infection and inflammation sites.
• Jubilant Radiopharma™ Mertiatide A renal function imaging agent used for diagnostic procedures to assess kidney structure and function.
• Jubilant Radiopharma™ Sulfur Colloid A radiopharmaceutical colloid used for liver imaging, bone marrow imaging, and gastrointestinal studies.
• HICON® Sodium Iodide I 131 Solution USP A therapeutic radiopharmaceutical solution containing iodine-131 used for treatment of hyperthyroidism and thyroid cancer.
• DRAXIMAGE® I-131 Diagnostic Capsules Capsule formulation of iodine-131 used for thyroid imaging and uptake studies.
• SMART-FILL® Dispensing System A specialized dispensing system for accurate measurement and delivery of radiopharmaceutical doses in clinical settings.
• DRAXIMAGE® MDP (Canada / Colombia market) A bone imaging agent used for skeletal scintigraphy to detect bone metastases and bone disorders, marketed in Canada and Colombia.
• DRAXIMAGE® Gluceptate A radiopharmaceutical used for brain imaging and soft tissue imaging studies (Canada market).
• DRAXIMAGE® I-131 Therapeutic Capsule Capsule formulation of iodine-131 used for therapeutic treatment of thyroid conditions (Canada market).
• DRAXIMAGE® I-131 Diagnostic Solution Liquid formulation of iodine-131 for thyroid diagnostic imaging (Canada market).
• DRAXIMAGE® I-131 Therapeutic Solution Liquid formulation of iodine-131 for therapeutic treatment of thyroid diseases (Canada market).

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Evergreen Theragnostics Inc.coreChannel Partner/ Reseller/ Distributor · 1 June 2023In June 2023, Jubilant DraxImage Inc. entered into a distribution agreement with Evergreen Theragnostics Inc. for the preparation, sale, and distribution of OCTEVY™ (Ga-68 DOTATOC Injection) doses to PET customers across the United States. This partnership expanded the company's product offerings in PET imaging diagnostics.
• Radiopharmacy PartnerscoreChannel Partner/ Reseller/ DistributorJubilant Radiopharma operates a network of radiopharmacy partners to extend distribution reach and provide localized preparation and delivery of radiopharmaceutical products to healthcare facilities.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Lantheus Holdings: Lantheus is a leading radiopharmaceutical-focused company with a portfolio spanning cardiac PET (PYLARIFY®), oncology, and diagnostics. Directly comparable to Jubilant Radiopharma in nuclear medicine product breadth and B2B sales to hospitals/imaging centers.
• Curium Pharma: Curium is one of the world's largest radiopharmaceutical manufacturers, with a diagnostic and therapeutic nuclear medicine portfolio across SPECT, PET, and therapeutic isotopes. Closely comparable in manufacturing scale, product mix, and target customer base.
• Bracco Imaging: Bracco Imaging is a global diagnostic imaging company offering contrast agents and radiopharmaceuticals for nuclear medicine and radiology. Comparable product mix and hospital/imaging-center customer base.
• Cardinal Health: Cardinal Health operates a large radiopharmacy distribution network (Nuclear Pharmacy Services) and supplies radiopharmaceuticals to hospitals across the US. Directly comparable as a radiopharmacy distributor serving the same hospital customer base.

Broad incumbents

• GE HealthCare: GE HealthCare operates a major radiopharmaceutical and PET radiopharmacy business (including PETNET Solutions) alongside broader imaging equipment. Overlaps with Jubilant in diagnostic radiopharmaceuticals but as part of a much larger portfolio.
• Novartis: Novartis leads radioligand therapy via Pluvicto and Lutathera and operates a broad pharmaceutical portfolio. Overlaps with Jubilant in the radiopharmaceutical category but at far greater scale and with a focus on therapeutics.
• Bayer: Bayer's radiology business includes radiopharmaceutical products and is cited as a key market player. Comparable in radiopharmaceutical product category but operates as part of a global pharmaceutical conglomerate.
• Eli Lilly (POINT Biopharma): Eli Lilly acquired POINT Biopharma and is developing a radioligand therapy pipeline in oncology. Comparable as a competitor in the radiopharmaceutical theranostics market cited alongside Jubilant in industry market projections.
• Siemens Healthineers: Siemens Healthineers offers radiopharmacy services and imaging solutions (PET/SPECT equipment and tracer supply) globally. Comparable in serving nuclear medicine departments and operating radiopharmacy supply chains.

Emerging players

• Telix Pharmaceuticals: Telix is a commercial-stage radiopharma company focused on diagnostic and therapeutic agents (e.g., Illuccix® for PSMA-PET). Comparable in product category and B2B hospital sales motion, with overlapping focus on PET imaging agents.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/102787441441932
• LinkedInlinkedin.com/company/jubilant-draximage

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jubilant Radiopharma